ProCE Banner Activity

To Treat or Not to Treat: The Conundrum of Immune-Tolerant Chronic HBV

Clinical Thought
Why I consider treatment for patients with immune-tolerant chronic HBV, and where I differ from current international guidance.

Released: May 14, 2021

Expiration: May 13, 2022

Share

Faculty

Ira M. Jacobson

Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from:

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

Ira M. Jacobson, MD, has disclosed that he has received funds for research support from Assembly, Bristol-Myers Squibb, Enanta, Genfit, Gilead Sciences, and Janssen and consulting fees from AbbVie, Arrowhead, Assembly, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, and Novo Nordisk.